Primidone

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released January 28, 2003; last updated January 20, 2017; expires January 20, 2020

Historical note and terminology

After the introduction of phenytoin, search for antiepileptic drugs with a structure similar to that of phenobarbital and phenytoin continued, and primidone was synthesized in 1949 (Bogue and Carrington 1953). It was introduced into clinical use in 1952 and found to be effective for the control of complex partial and secondarily generalized seizures (Handley and Stewart 1952). There has been some controversy as to whether it is a distinct antiepileptic drug or simply a prodrug of phenobarbital. Most investigations now suggest that primidone has pharmacodynamic properties distinct from those of phenobarbital. The manufacturer of primidone has announced the discontinuation of this drug. Primidone was withdrawn from the market in the Netherlands in 2004 but was available for some time on a limited basis (de Haan et al 2003). In the United Kingdom, the drug will be available until an alternative source of manufacture is found.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.